→ The first fruits of 23andMe’s ef­forts to gen­er­ate new drugs off the in­sights it gained from a mas­sive amount of ge­net­ic da­ta are tak­ing shape, and Almi­rall is sign­ing up to ripen one of them. The Span­ish der­ma­tol­ogy drug­mak­er has li­censed a bis­pe­cif­ic an­ti­body that blocks three cy­tokines in the IL-36 cy­tokine fam­i­ly, which are tied to skin con­di­tions such as pso­ri­a­sis and lu­pus, in ad­di­tion to oth­er in­flam­ma­to­ry ail­ments such as ul­cer­a­tive col­i­tis, in­flam­ma­to­ry bow­el dis­ease, and Crohn’s dis­ease.

“As a leader in med­ical der­ma­tol­ogy, we felt Almi­rall was the best com­pa­ny to take this pro­gram for­ward and ul­ti­mate­ly de­vel­op an ef­fec­tive ther­a­py for pa­tients,” Ken­neth Hillan, who suc­ceed­ed Genen­tech vet Richard Scheller as head of ther­a­peu­tics at 23andMe, said in a state­ment.

While it start­ed out as a di­rect-to-con­sumer test­ing ser­vice, 23andMe has moved deep­er in­to the ther­a­peu­tic space in re­cent years, most no­tably through a $300 mil­lion part­ner­ship with Glax­o­SmithK­line.

→ We now know the iden­ti­ty of Idor­sia’s mys­tery part­ner from last year. The Swiss biotech — spun out from J&J’s Acte­lion buy­out — had an­nounced that it pock­et­ed a $5 mil­lion pay­ment from an undis­closed par­ty to score a li­cens­ing op­tion on ACT-709478, a brain pen­e­trat­ing T-type cal­ci­um chan­nel block­er. Now we learn that Neu­ro­crine will pay $45 mil­lion if it ex­er­cis­es the op­tion and up to $365 mil­lion in mile­stones.

“We are ex­cit­ed to lever­age the sci­en­tif­ic ex­per­tise of Idor­sia in T-type cal­ci­um chan­nel in­hi­bi­tion to po­ten­tial­ly ad­vance a Phase 2 ready com­pound to help peo­ple suf­fer­ing from epilep­sy. In ad­di­tion to the treat­ment of epilep­sy, the mod­u­la­tion of the cal­ci­um chan­nel may be use­ful for the treat­ment of oth­er dis­or­ders such as es­sen­tial tremor and pain,” Kevin Gor­man, the CEO at Neu­ro­crine, said in a state­ment.

→ Phase­Bio has found a deep-pock­et­ed be­liev­er in its blood thin­ner re­ver­sal agent: SFJ Phar­ma­ceu­ti­cals, which has of­fered up to $120 mil­lion to sup­port the clin­i­cal de­vel­op­ment of PB2452. First li­censed from As­traZeneca, the “break­through” drug is de­signed to can­cel the ef­fects of tica­grelor, an an­ti­co­ag­u­lant, in ur­gent or sur­gi­cal sit­u­a­tions. Backed by Black­stone Life Sci­ences and Abing­worth, SFJ will al­so take over the bulk of the clin­i­cal and reg­u­la­to­ry work out­side of the US. In ex­change, Phase­Bio will pay an­nu­al lump sums once (and if) they win ap­provals.

→ Boehringer In­gel­heim Ven­ture Fund and Dutch in­vestor PPF are lead­ing a $22 mil­lion Se­ries C round for Basel, Switzer­land-based NBE Ther­a­peu­tics to bankroll ear­ly clin­i­cal tri­als of its lead as­set. Rid­ing on re­newed en­thu­si­asm for an­ti­body-drug con­ju­gates, NBE said their plat­form tech is both more pow­er­ful and safer than the ear­li­er gen­er­a­tions of ADC, be­ing im­mune-stim­u­la­to­ry and em­ploy­ing an an­thra­cy­cline pay­load. NBE-002 tar­gets ROR1 in triple-neg­a­tive breast can­cer and lung can­cer, to be fol­lowed by oth­er sol­id can­cer types and lym­phomas.

→ While await­ing an FDA de­ci­sion on its sec­ond shot at an ap­proval, Aca­cia Phar­ma has in-li­censed a short-act­ing, re­versible in­tra­venous seda­tive/anes­thet­ic from Cos­mo Phar­ma. The €10 mil­lion up­front pay­ment will take the form of an eq­ui­ty sale, with an­oth­er €30 mil­lion due up­on US ap­proval of the drug, By­Fa­vo, and more com­mer­cial mile­stones. “Hav­ing a sec­ond prod­uct that shares the same call­ing points and at­trac­tive com­mer­cial mes­sage as Barhem­sys will make the in­vest­ment in our sales and mar­ket­ing teams more ef­fi­cient,” CEO Mike Bolin­der said in a state­ment.

→ Eye-fo­cused gene ther­a­py de­vel­op­er Eye­ven­sys has scored $30 mil­lion in Se­ries B fund­ing with the help of lead in­vestor Boehringer In­gel­heim Ven­ture Fund. Pon­tif­ax, Bpifrance, CapDe­cisif, In­serm Trans­fert, the Glob­al Health Sci­ences Fund and Pure­os Bioven­tures al­so joined to boost their R&D ef­forts, fea­tur­ing a lead Phase II-ready pro­gram for chron­ic non-in­fec­tious uveitis.

→ The cell ther­a­py ex­perts at Jasper Ther­a­peu­tics have brought in an ex­tra $14.1 mil­lion for their Se­ries A, adding Roche Ven­ture Fund to their ros­ter of mar­quee in­vestors. The new cash will help ex­pand the lead clin­i­cal pro­gram, a CD117-tar­get­ed an­ti­body con­ceived as an al­ter­na­tive con­di­tion­ing reg­i­men be­fore stem cell trans­plants.

→ Fol­low­ing the close of its $1 bil­lion-plus sec­ond fund, GHO Cap­i­tal Part­ners has ac­quired Bel­gian CD­MO Ar­de­na, which is fo­cused on ear­ly-stage drug de­vel­op­ment, from Men­tha Cap­i­tal.

In the insular world of biotech, a spectacular failure can sometimes stay on any executive’s record for a long time. But for David Meek, the man at the helm of FerGene’s recent implosion, two questionable exits made way for what could be an excellent rebound.

Meek, most recently FerGene’s CEO and a past head at Ipsen, has become CEO at Mirati Therapeutics, taking the reins from founding CEO Charles Baum, who will step over into the role of president and head of R&D, according to a release.

The biotech industry has faced repeated calls to diversify its workforce — and in the last year, those calls got a lot louder. Though women account for just under half of all biotech employees around the world, they occupy very few places in C-suites, and even fewer make it to the helm.

Some companies are listening, according to a recent BIO survey which showed that this year’s companies were 2.5 times more likely to have a diversity and inclusion program compared to last year’s sample. But we still have a long way to go. Women represent just 31% of biotech executives, BIO reported. And those numbers are even more stark for women of color.

A week before the FDA is set to decide on Mirum Pharmaceuticals’ lead liver disease drug — an old Shire cast-off called maralixibat — Takeda is swooping in to secure the rights in Japan.

Maralixibat’s roots trace back to Lumena, which was snapped up by Shire for $260 million-plus back in 2014. While the candidate had failed mid-stage studies at Shire, Mirum believes better trial design and patient selection will deliver the wins it needs. The drug is currently in development for Alagille syndrome (a condition called ALGS in which bile builds up in the liver), progressive familial intrahepatic cholestasis (PFIC, which causes progressive liver disease) and biliary atresia (a blockage in the ducts that carry bile from the liver to the gallbladder).